PCI-27483

Cat. No.: HY-16382
CAS No.: 871266-63-6
Molecular Formula: C₂₆H₂₄N₆O₉S
Molecular Weight: 596.57
Target: Others
Pathway: Others
Storage: Powder
-20°C 3 years
4°C 2 years
In solvent
-80°C 6 months
-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro
DMSO : 62.5 mg/mL (104.77 mM; Need ultrasonic)

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>1.6762 mL</td>
<td>8.3812 mL</td>
<td>16.7625 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.3352 mL</td>
<td>1.6762 mL</td>
<td>3.3525 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.1676 mL</td>
<td>0.8381 mL</td>
<td>1.6762 mL</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

In Vivo
1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (3.49 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (3.49 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (3.49 mM); Clear solution

BIOLOGICAL ACTIVITY

Description
PCI-27483 is a FVIIa/tissue factor inhibitor, with antitumour effects.

In Vitro
PCI-27483 inhibits the TF:FVIIa-complex induced phosphorylation of ERK1/2 and subsequent induction of c-fos in BxPC3 cells, a human pancreatic adenocarcinoma line that highly expresses TF. Furthermore, PCI-27483 blocks the TF:FVIIa induced secretion of IL8 in both BxPC3 cells and MDA-MB-231 breast cancer cells[2].
In Vivo

PCI-27483 shows dose-dependent inhibition of thrombus formation, fibrin accumulation and PT. PCI-27483 (4 mg/kg) shows comparable anticoagulation effects as 2 mg/kg enoxaparin[1]. PCI-27483 (0 and 90 mg/kg, s.c.) results in inhibition of tumor growth in CD1 nu/nu mice implanted with BxPC3 cells[2].

REFERENCES
